Dual specificity protein kinase CLK4
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dual specificity protein kinase CLK4 as ChEMBL target CHEMBL4203, mapped to UniProt Q9HAZ1. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Dual specificity protein kinase CLK4 matters
Dual specificity protein kinase CLK4 is reviewed as Dual specificity protein kinase CLK4 (UniProt Q9HAZ1); the current evidence base includes 17 approved drugs, 2938 compounds, and 312 assays, with lead potency reaching pChEMBL 9.5.
Dual specificity protein kinase CLK4 Sequence length is 481 aa.
Review this target as Dual specificity protein kinase CLK4, mapped to UniProt Q9HAZ1. Sequence length is 481 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 17 approved drugs, 2938 compounds, and 312 assays for this target. The dominant activity type is KI. CHEMBL1980407 is the current potency anchor at pChEMBL 9.5.
Use CHEMBL1980407 as the tractability anchor when discussing potency (pChEMBL 9.5).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Dual specificity protein kinase CLK4 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q9HAZ1, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1980407
|
9.5 | Ki | — |
|
|
No preferred name
CHEMBL379218
|
9.3 | Kd | — |
|
|
No preferred name
CHEMBL4797564
|
9.2 | IC50 | — |
|
|
No preferred name
CHEMBL4797564
|
9.2 | Kd | — |
|
|
No preferred name
CHEMBL2007574
|
9.2 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CAPIVASERTIB
CHEMBL2325741
|
2023 |
|
|
ENTRECTINIB
CHEMBL1983268
|
2019 |
|
|
ABEMACICLIB
CHEMBL3301610
|
2017 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
PALBOCICLIB
CHEMBL189963
|
2015 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
SUNITINIB
CHEMBL535
|
2006 |